Related Experiment Videos
Restoring p53-dependent tumor suppression
Wenge Wang1, Farzan Rastinejad, Wafik S El-Deiry
1Laboratory of Molecular Oncology and Cell Cycle Regulation; Howard Hughes Medical Institute; University of Pennsylvania School of Medicine; Philadelphia, Pennsylvania 19104, USA. wafik@mail.med.upenn.edu
Cancer Biology & Therapy
|September 26, 2003
Summary
The p53 tumor suppressor protein is a key target for anti-cancer drug development. Researchers are exploring ways to restore p53 function in cancer cells to trigger tumor cell death.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The p53 protein is a critical tumor suppressor frequently mutated or inactivated in human cancers.
- Restoring p53 function presents a promising strategy for anti-cancer therapy, as it can induce apoptosis in tumor cells.
Purpose of the Study:
- To explore therapeutic strategies targeting the p53 pathway in cancer.
- To investigate methods for restoring the tumor-suppressing function of both wild-type and mutant p53.
Main Methods:
- Gene delivery of wild-type p53 into cancer cells.
- Modulating p53 degradation pathways (e.g., via ARF or MDM2).
- Screening chemical libraries for compounds that restore mutant p53 activity, such as CP-31398 and PRIMA-1.
Main Results:
- Gene delivery of wild-type p53 effectively suppressed tumor growth.
- Inhibiting p53 degradation pathways induced tumor cell death.
- Small molecules like CP-31398 and PRIMA-1 were identified that can restore function to mutant p53 by stabilizing its active conformation.
Conclusions:
- Targeting the p53 pathway, including restoring function to mutant p53, is a viable anti-cancer strategy.
- The identified small molecules offer potential for developing novel p53-based cancer therapeutics.